The National Institute of Allergy and Infectious Diseases has launched a clinical trial to study rare but potentially serious allergic reactions to COVID-19 mRNA vaccines. The trial is seeking 100 participants ages 16-69 years of age who had a mild or moderate allergic reaction following their first dose of a COVID mRNA vaccine. Participants will be admitted to the ICU at the National Institutes of Health's (NIH's) Clinical Center in Bethesda, Maryland, where they will receive a second dose of vaccine under monitored conditions with medical staff administering frequent tests to detect any allergic reactions.

The study aims to provide a better understanding of the mechanisms responsible for allergic reactions to mRNA vaccines and will help determine whether people who experienced allergic reactions to one dose of vaccine can safely receive a second dose.


The Human Rights Campaign (HRC) has released their 15th annual Healthcare Equality Index (HEI)...

You do not currently have access to this content.